Serum Patents (Class 424/531)
-
Patent number: 6372262Abstract: The present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm. The molecular weight of said SDF was determined by electron spray mass spectrometry and is of 316 Da. SDF of the present invention or its complex with ceruloplasmin (CP) have several therapeutic properties. For example, SDF or its complex with CP is capable of inducing terminal cell differentiation of leukemic cells, which as a result, may lose their ability to proliferate and their ability for self cell renewal. Further, SDF or the complex with CP is capable of stimulating the proliferation of early, normal progenitor cells and inhibiting enhanced angiogenesis. In addition, SDF or its complex with CP is capable of ex vivo expanding normal stem and progenitor cells.Type: GrantFiled: June 8, 1999Date of Patent: April 16, 2002Assignee: Hadasit Medical Research Services & Development Company Ltd.Inventors: Tony Peled, Eitan Fibach, Eliezer A. Rachmilewitz
-
Publication number: 20010043928Abstract: Serum preparations obtained from sharks are used to prepare compositions, including pharmaceutical compositions, for inhibiting retrovirus replication in susceptible cells. Thus, the serum preparations are useful for inhibiting diseases associated with retroviral infection, such as acquired immunodeficiency syndrome. The serum concentrates are also used to inhibit growth of tumor cells, especially sarcomas and leukemias.Type: ApplicationFiled: February 21, 2001Publication date: November 22, 2001Inventor: Mark E. Howard
-
Patent number: 6312733Abstract: Ice crystal growth inhibiting agents and process for preparing an extract of these agents in which Zoarces viviparus blood is extracted, it is cooled, the supernatant constituting the Zoarces viviparus serum containing the ice crystal growth inhibiting agents is collected, and then the supernatant is frozen. The present invention also relates to a process for using these agents for the manufacture of a food product.Type: GrantFiled: March 8, 2000Date of Patent: November 6, 2001Assignee: Nestec S.A.Inventors: Alfred Jann, Rolv Lundheim
-
Patent number: 6303152Abstract: A process is disclosed for the production of immune-genetically active suspensions of which the initial substances are fluids or tissues from the human or animal body. Autohemotherapy, immune-stimulatory and/or immune-suppressive effects are employed. The suspensions thus produced can be used as pooled sera as desired.Type: GrantFiled: March 15, 1993Date of Patent: October 16, 2001Inventor: Horst Kief
-
Patent number: 6284285Abstract: A method for isolating tissue repair promoting substances from human or animal blood, which method comprises collecting the human or animal blood from a single human or animal individual in a first container of a container system comprising at least first and second interconnected containers; centrifuging the container system containing said blood so as to separate the blood in various fractions including a plasma fraction; transferring at least part of the plasma fraction to said second container of the container system; subjecting the plasma fraction in said second container to a low temperature so as to obtain a precipitate comprising tissue repair promoting substances; concentrating said precipitate in said second container so as to obtain a first fraction comprising a major part of the non-precipitated material, and a second fraction comprising at least the major part of the precipitate and a minor part of the non-precipitated material; and separating said second fraction comprising the tissue repair proType: GrantFiled: December 29, 1992Date of Patent: September 4, 2001Assignee: E. R. Squibb & Sons, Inc.Inventor: Ulla Sivertsen Weis-Fogh
-
Publication number: 20010006682Abstract: A method of treating patients having suppressed immune systems by perenterally administering Product R, a peptide-nucleic acid preparation, alone or in a combination with one or more immuno-modulators, is disclosed.Type: ApplicationFiled: April 15, 1997Publication date: July 5, 2001Inventor: SHALOM Z. HIRSCHMAN
-
Patent number: 6224913Abstract: Conditioning of the surface of silica-based glass or ceramic by differential immersion in a serum protein-containing solution, and the resultant microporous Ca—P surface layer having serum-protein like organic molecules, as defined herein intermingled throughout, is described.Type: GrantFiled: November 24, 1997Date of Patent: May 1, 2001Assignee: The Trustees of the University of PennsylvaniaInventors: Paul Ducheyne, Shulamith Radin
-
Patent number: 6214357Abstract: The present invention provides methods for using a killed malaria parasite or an extract thereof in the treatment of non-insulin dependent diabetes mellitus (NIDDM).Type: GrantFiled: November 30, 1999Date of Patent: April 10, 2001Assignee: Rademacher Group LimitedInventors: John Hugh Lyon Playfair, Khaled Elased, Joseph Brian De Souza
-
Patent number: 6207807Abstract: A peptide of formula (I) (H2N—X1—Thr—X2—CO)n—R (I) where X1 and X2, different one another, are an amino acid residue of arginine or tyrosine in configuration L or D, wherein the hydroxy group of threonine and tyrosine and the guanidine moiety of arginine may be protected by a compound conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 1,2, 3 or 4, and R, when n is 2,3 or 4, is a group suitable for forming a dimer, trimer or tetramer, while, when n is 1, R is OH, a single amino acid residue, or a peptide chain containing up to 7 amino acid residues.Type: GrantFiled: December 3, 1998Date of Patent: March 27, 2001Assignee: Tecnogen S.C.p.A,Inventors: Giorgio Fassina, Antonio Verdoliva, Menotti Ruvo
-
Patent number: 6143330Abstract: Compositions for treating or preventing dental caries and/or middle ear infections. These compositions comprise antibodies to dental caries and/or antibodies to bacteria causing middles ear infections and/or an agent preventing the adhesion, accumulation or reporduction of the pathogens of tooth or middle ear. The preferred agent is xylitol. Methods for using these compositions are also included.Type: GrantFiled: August 24, 1998Date of Patent: November 7, 2000Inventors: Antti Sakari Aaltonen, Jouko Suhonen
-
Patent number: 6084074Abstract: A stabilized aqueous liquid preparation of human blood coagulation factor XIII, prepared by recombinant DNA technology, from the group consisting of galactose, sucrose, sorbitol, glutamate, aspartate and histidine and where little reduction in biological activity occurs even when stored for a longer time.Type: GrantFiled: June 5, 1996Date of Patent: July 4, 2000Assignee: Centeon Pharma GmbHInventors: Naoko Kato, Shuji Kondo
-
Patent number: 6071919Abstract: A method of treating a disease in a mammal by administering a therapeutic effective amount of an amphoteric zwitterion compound as an active ingredient. A pharmaceutical composition which comprises an amphoteric zwitterionic compound as an active ingredient in combination with a carrier and other adjunctive pharmaceutical agents.Type: GrantFiled: November 2, 1998Date of Patent: June 6, 2000Assignee: T. Ronald TheodoreInventors: T. Ronald Theodore, Roscoe L. Van Zandt
-
Patent number: 6033688Abstract: The invention provides methods for treating cystic fibrosis and other pathological conditions in mammals using hepatocyte growth factor ("HGF"). The invention also provides articles of manufacture and kits containing HGF.Type: GrantFiled: September 2, 1997Date of Patent: March 7, 2000Assignees: Genentech, Inc., The Regents of the University of California, Children's Hospital Medical Center of Northern CaliforniaInventors: Randall J. Mrsny, Ben-Quan Shen, Jonathan H. Widdicombe
-
Patent number: 6007979Abstract: A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in thatsaid potentially infectious material for the isolation of said biologically active substances is treated witha hydrophobic phase which is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, andsaid hydrophobic phase is separated from the potentially infectious material thus treated.Type: GrantFiled: February 19, 1998Date of Patent: December 28, 1999Assignee: Octapharma AGInventors: Wolfgang Marguerre, Horst Schwinn, Lothar Biesert
-
Patent number: 5981284Abstract: A first embodiment of a cell culture system has a cell death accelerator comprising one or more cell death inducing substances, including serum albumin, hemoglobin, glycine and glutamic acid. In a second embodiment a cell death inhibitor comprises one or more kinds of cell death inhibiting substances which include mercapto group containing amino acids, other mercapto group containing compounds and tryptophan. In a third embodiment a cell death inhibitor comprises an inhibitor of RNA or protein synthesis, optionally augmented with a thiol. The system can be applied to selectively induce death of cultured cells, such as neoplastic cell lines, or to inhibit death of other cells, such as neoplastic cell lines or non-neoplastic cells such as brain cells.Type: GrantFiled: May 22, 1998Date of Patent: November 9, 1999Assignee: Discovision AssociatesInventors: Hideo Namiki, Takeshi Kurita
-
Patent number: 5968759Abstract: The invention relates to a method for the quantification of coagulation factor VIIa (F VIIa) in FVIIa- or FVII/FVIIa-containing solutions by means of selective binding to immobilized soluble thromboplastin.Type: GrantFiled: October 16, 1996Date of Patent: October 19, 1999Assignee: Centeon Pharma GmbHInventors: Jurgen Romisch, Hans-Arnold Stohr
-
Patent number: 5945297Abstract: The present invention provides a method for screening candidate agents to identify compounds that modulate the hemostatic system. The method of the invention involves a screening medium comprised of stored whole blood, preferably diluted with buffer, to which unrefrigerated platelets have been added. Candidate agents that may inhibit or activate clot formation or clot lysis are added to the screening medium and suitable compounds are identified. The assay provided is physiologically relevant, rapid, inexpensive and allows for large scale screening of candidate agents.Type: GrantFiled: April 29, 1998Date of Patent: August 31, 1999Assignee: MetaXen LLCInventor: Albert P. Gadbut
-
Patent number: 5861158Abstract: This invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic cell tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's hematopoietic cell tumor, and transplanting the donor's immunized hematopoietic cells to the recipient. Also provided is a composition comprising purified hematopoietic cells primed to produce an immunological response to foreign tumor specific antigen. Also provided is a method of treating a tumor by the transplantation of hematopoietic cells from a donor to a recipient to treat the tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's tumor, and transplanting the donor's immunized hematopoietic cells to the recipient.Type: GrantFiled: November 17, 1993Date of Patent: January 19, 1999Assignee: The United States of America as represented by the Deptartment of Health and Human ServicesInventors: Larry W. Kwak, Dan L. Longo
-
Patent number: 5855918Abstract: The invention provides methods for treating cystic fibrosis and other pathological conditions in mammals using hepatocyte growth factor ("HGF"). The invention also provides articles of manufacture and kits containing HGF.Type: GrantFiled: September 12, 1996Date of Patent: January 5, 1999Assignees: Genentech, Inc., Children's Hospital Medical Center of Northern California, Regents of the University of CAInventors: Randall J. Mrsny, Ben-Quan Shen, Jonathan H. Widdicombe
-
Patent number: 5792479Abstract: A first embodiment of a cell culture system has a cell death accelerator comprising one or more cell death inducing substances, including serum albumin, hemoglobin, glycine and glutamic acid. In a second embodiment a cell death inhibitor comprises one or more kinds of cell death inhibiting substances which include mercapto group containing amino acids, other mercapto group containing compounds and tryptophan. In a third embodiment a cell death inhibitor comprises an inhibitor of RNA or protein synthesis, optionally augmented with a thiol. The system can be applied to selectively induce death of cultured cells, such as neoplastic cell lines, or to inhibit death of other cells, such as neoplastic cell lines or non-neoplastic cells such as brain cells.Type: GrantFiled: December 11, 1996Date of Patent: August 11, 1998Assignee: Discovision AssociatesInventor: Hideo Namiki
-
Patent number: 5776452Abstract: The invention provides compositions having thrombolytic effects, and comprise plasmin and a plasminogen activator. Such compositions can be administered locally or systemically. The invention also provides simple and safe therapies for thrombotic states and prevention of such states.Type: GrantFiled: March 27, 1995Date of Patent: July 7, 1998Assignee: Immuno AktiengesellschaftInventors: Johann Eibl, Anton Philapitsch, Hans Peter Schwarz
-
Human serum albumin-porphyrin complexes with the ability to bind oxygen and therapeutic uses thereof
Patent number: 5773417Abstract: The invention is directed to human serum albumin-porphyrin (HSA-P) complexes which are capable of reversible oxygen binding and their uses. These complexes may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or in applications requiring plasma expanders. Methods for the production of these complexes are provided. In a specific example, HSA-P complexes are shown to exhibit reversible oxygen binding. In another example, the HSA-P complex does not exhibit appreciable vasoactivity.Type: GrantFiled: August 6, 1997Date of Patent: June 30, 1998Assignee: Duke UniversityInventor: Joseph Bonaventura -
Patent number: 5773026Abstract: The invention is a carotenoid agent for inhibiting the conversion of epithelial cells to tumours, the agent including an effective amount of a water insoluble carotenoid component in a suitable non-toxic carrier medium.Type: GrantFiled: September 22, 1995Date of Patent: June 30, 1998Assignee: Betatene LimitedInventor: Lance Elliott Schlipalius
-
Patent number: 5759764Abstract: A simple, inexpensive, physiologically compatible, cryopreservation solution which includes the innocuous components of (i) glycerol, (ii) an alkali metal chloride salt, (iii) a monosaccharide, and (iv) serum albumin.Type: GrantFiled: May 31, 1996Date of Patent: June 2, 1998Assignee: Celox Laboratories, Inc.Inventor: Milo R. Polovina
-
Patent number: 5747653Abstract: A vaccine effective against infection caused by group B Nesseria meningitidis microorganism is provided which comprises a purified protein antigenic complex weighing from 65 to 95 kDa, vesicles, and capsular polysaccharides. This vaccine is extracted from the cell membranes of the live microorganisms using detergent and enzyme. The method of producing an antimeningococcic hyperimmune gammaglobulin and the gammaglobulin produced by the method was provided. The gammaglobulin is obtained from vaccinees vaccinated with the vaccine.Type: GrantFiled: August 2, 1996Date of Patent: May 5, 1998Assignee: Centro Nacional De BiopreparadosInventors: Concepcion Campa Huergo, Victoriano Gustavo Sierra Gonzalez, Maria Mercedes Gutierrez Vazcuez, Gonzalo Bisset Jorrin, Luis Guillermo Garcia Imia, Gisela de la Caridad Puentes Rizo, Maria del Carmen Sampedro Herrera, Franklin Sotolongo Padron, Eloisa Xochitl Le Riverend Morales, Manuel Alfredo Galguera Dominguez
-
Patent number: 5731007Abstract: The present invention relates to novel pharmaceutical composition for skin diseases, in particular to novel pharmaceutical composition useful for treatment of skin diseases; e.g. burns, wounds, general operative wounds, pernio, decubitus, folliculitis, impetigo, intertrigo, radiation ulcer, acne vulgaris or infectious eczematous dermatitis comprising deproteinized dialysate of calf's blood with tissue regenerative activity and aminoglycoside antibiotic with bacterial infection inhibitory activity as active ingredients.Type: GrantFiled: July 25, 1996Date of Patent: March 24, 1998Assignee: Yungjin Pharmaceutical Co., Ltd.Inventors: Kae Jong Chung, Man Sik Chang, Jong Ok Chun, Jae Kwang Chun, Wahn Soo Choi, Sung Chul Kim
-
Patent number: 5716959Abstract: A substituted piperazine zwitterion composition containing, for example, as an active ingredient, HEPES (N-2 Hydroxyethylpiperazine-N'-2 Ethane Sulfonic Acid), and method useful for treatment of cancer, autoimmune, arthritis and other mammalian diseases.Type: GrantFiled: February 13, 1996Date of Patent: February 10, 1998Assignee: T. Ronald TheodoreInventors: T. Ronald Theodore, Roscoe L. Van Zandt
-
Patent number: 5705607Abstract: The present invention provides the technique for isolating the toxin of the Sarcocystis protozoa, which may be later used in the production of specific antibodies against the sarcocystine responsible for the symptoms of sarcocystosis. The technique of the invention consists of separating the blood serum of an infected animal followed by dialysis thereof and finally the sample is dried. The technique is more effective when heart muscle material from an intermediate host with Sarcocystis cysts is used to contaminate a carnivorous mammal final host.Type: GrantFiled: July 12, 1996Date of Patent: January 6, 1998Inventor: Jose Luis Azumendi
-
Patent number: 5667811Abstract: The invention provides methods for obtaining substantially purified high and low molecular weight Na-K-ATPase inhibitor compounds having natriuretic and vasoconstrictive activity, antibodies reactive with the compounds and methods for their use in diagnostic and therapeutic applications to detect elevated or decreased amounts of the compounds in subjects having diseases associated with the presence or deficiency of these natriuretic compounds.Type: GrantFiled: November 30, 1992Date of Patent: September 16, 1997Assignee: The Regents of the University of CaliforniaInventors: Harvey C. Gonick, Elmar Weiler, Farhad Khalil-Manesh
-
Patent number: 5643192Abstract: A fibrin glue includes a fibrinogen component and a thrombin component, both prepared from single donor plasma. The plasma is precipitated to produce a precipitate containing fibrinogen and a supernatant containing the thrombin. The precipitate may be resuspended in a small volume of supernatant and used as the fibrinogen component. The supernatant is further treated by clotting to convert residual fibrinogen to fibrin and filtration to remove the fibrin. The resulting serum can be used as the thrombin component.Type: GrantFiled: April 6, 1995Date of Patent: July 1, 1997Assignee: Hamilton Civic Hospitals Research Development, Inc.Inventors: Jack Hirsh, Marilyn Johnston, Kevin Teoh
-
Patent number: 5595735Abstract: A hemostatic paste composition comprising a hemostatic effective amount of thrombin in a polyethylene glycol base which is preferably prepared by admixing an aqueous solution of thrombin and polyethylene glycol and freeze-drying the mixture to remove substantially all of the water to yield a viscous water soluble paste of fine particles of thrombin uniformly dispersed throughout the polyethylene glycol base, and methods of its use to provide hemostasis to a hemorrhaging site of a mammal.Type: GrantFiled: May 23, 1990Date of Patent: January 21, 1997Assignee: Johnson & Johnson Medical, Inc.Inventors: Lowell Saferstein, Stephen J. Wolf
-
Patent number: 5589516Abstract: A liquid preparation of antithrombin-III (AT-III), comprising an AT-III and an organic acid, a salt thereof, a sugar sulfate or a surfactant as a stabilizer, and a liquid preparation of AT-III, having a pH of 9-10. The preparation of the present invention is stable after long-term preservation and poses no clinical problems in terms of pharmacological effects and safety. The preparation is more advantageous than lyophilized preparations in that it does not require dissolution in injectable distilled water and can be used easily. Accordingly, the preparation is clinically very useful.Type: GrantFiled: December 5, 1994Date of Patent: December 31, 1996Assignee: The Green Cross CorporationInventors: Katsuhiro Uriyu, Akimasa Ohmizu, Hajime Fukuyama, Kazuo Takechi, Kazumasa Yokoyama
-
Patent number: 5580714Abstract: A simple, inexpensive, physiologically compatible, cryopreservation solution which includes the innocuous components of (i) glycerol, (ii) an alkali metal chloride salt, (iii) a monosaccharide, and (iv) serum albumin.Type: GrantFiled: March 8, 1995Date of Patent: December 3, 1996Assignee: Celox Laboratories, Inc.Inventor: Milo R. Polovina
-
Patent number: 5578326Abstract: A method for isolating tissue repair promoting substances from human or animal blood, which method comprises collecting the human or animal blood from a single human or animal individual in a first container of a container system comprising at least first and second interconnected containers; centrifuging the container system containing the blood so as to separate the blood in various fractions including a plasma fraction; transferring at least part of the plasma fraction to the second container of the container system; subjecting the plasma fraction in the second container to a low temperature so as to obtain a precipitate comprising tissue repair promoting substances; concentrating the precipitate in the second container so as to obtain a first fraction comprising a major part of the non-precipitated material, and a second fraction comprising at least the major part of the precipitate and a minor part of the non-precipitated material; and separating the second fraction comprising the tissue repair promotingType: GrantFiled: May 12, 1995Date of Patent: November 26, 1996Assignee: E. R. Squibb & Sons, Inc.Inventor: Ulla S. Weis-Fogh
-
Patent number: 5545516Abstract: This invention provides methods for inactivating pathogenic contaminants in whole blood, plasma, cellular blood components, or in any combination thereof, by adding a phenthiazin-5-ium dye(s) thereto and irradiating said dye-containing composition for an effective length of time with light of wavelengths from 560 to 800 nm or red light, of an effective intensity, whereby the irradiation in conjunction with the dye(s) inactivate substantially all pathogenic contaminants contained therein. The methods of this invention inactivate pathogenic contaminants, such as viruses, bacteria and parasites, without substantially altering the whole blood, plasma, cellular blood components, or combinations thereof, such that they are suitable for transfusion.Type: GrantFiled: February 18, 1994Date of Patent: August 13, 1996Assignee: The American National Red CrossInventor: Stephen J. Wagner
-
Patent number: 5510121Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carders to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.Type: GrantFiled: May 4, 1995Date of Patent: April 23, 1996Inventors: Woonza M. Rhee, Richard A. Berg
-
Patent number: 5498540Abstract: A method for culturing insect cells using fish serum. The method uses serum extracted from the blood of fish to culture insect cells for various purposes. The technique has the key advantages of consistent quality, low cross reactivity, safety from infectious agents that would endanger researchers or humans and animals receiving cell culture products as therapy and has appropriate nutrients to maintain the growth of insect cells. Fish serum is used together with designated defined medium to allow insect cells to grow and populations to be maintained. The method may also be used with lumpfish to prevent the attachment of insect cells to cultureware. Serum is derived from the blood of captive stocks of fishes raised under control conditions.Type: GrantFiled: December 22, 1994Date of Patent: March 12, 1996Assignee: Sea Run Holdings, Inc.Inventors: Evelyn S. Sawyer, Philip J. Sawyer
-
Patent number: 5464816Abstract: A pharmaceutical composition containing serum thymic factor (FTS) and a method for using FTS containing compositions for treating a variety of immunodeficiencies and autoimmune diseases including multiple sclerosis, Guillain-Barre syndrome, inflammatory neuropathy, polyneuritis and other immunodemyelinating diseases.Type: GrantFiled: March 26, 1990Date of Patent: November 7, 1995Assignee: Mitsui Pharmaceuticals Inc.Inventors: Yoshitaka Nagai, Hayao Abe, Masanobu Arita
-
Patent number: 5453354Abstract: The present invention relates to a macromolecule of proteinaceous nature which activates sperm motility, a process for the preparation thereof by purification of the macromolecule from extracellular fluids, pharmaceutical preparations containing the macromolecule and antibodies directed against determinants specific to the macromolecule and the use thereof as a method to assay the potential fertility of sperm.Type: GrantFiled: August 18, 1993Date of Patent: September 26, 1995Assignees: Eva Akerlof, Ake Pousette, Applied Research Systems ARS Holding N.V.Inventors: Eva Akerlof, Ake Pousette
-
Patent number: 5443984Abstract: A method for culturing mammalian cells using fish serum. The method uses serum extracted from the blood of fishes to culture mammalian cells for various purposes. The technique has the key advantages of 1) freedom from mammalian infectious agents that could contaminate cell lines or endanger researchers or recipients of therapeutants derived from mammalian cell culture; 2) consistent and reproducible serum content and quality; 3) low cross-reactivity; and 4) provision of the appropriate serum nutrients to maintain the growth of mammalian cells. Fish serum is used together with designated defined media to allow mammalian cells to grow and populations of these cells to be maintained. Blood serum is derived from captive stocks of fish raised under controlled conditions such that the diet, habitat, genetics, life history, and reproductive status of the fish remains substantially consistent and reproducible.Type: GrantFiled: December 22, 1994Date of Patent: August 22, 1995Assignee: Sea Run Holdings, Inc.Inventors: Evelyn S. Sawyer, Philip J. Sawyer
-
Patent number: 5426045Abstract: A method for culturing mammalian cells using fish serum. The method uses serum extracted from the blood of fishes to culture mammalian cells for various purposes. The technique has the key advantages of 1) freedom from mammalian infectious agents that could contaminate cell lines or endanger researchers or recipients of therapeutants derived from mammalian cell culture; 2) consistent and reproducible serum content and quality; 3) low cross-reactivity; and 4) the appropriate serum nutrients to maintain the growth of mammalian cells. Fish serum is used together with designated defined media to allow mammalian cells to grow and populations of these cells to be maintained. Blood serum is derived from captive stocks of fish raised under controlled conditions such that the diet, habitat, genetics, life history, and reproductive status of the fish remains substantially consistent and reproducible.Type: GrantFiled: June 21, 1994Date of Patent: June 20, 1995Assignee: Sea Run Holdings, Inc.Inventors: Evelyn S. Sawyer, Philip J. Sawyer
-
Patent number: 5418130Abstract: A method is provided for inactivating viral and/or bacterial contamination in blood cellular matter, such as erythrocytes and platelets, or protein fractions. The cells or protein fractions are mixed with chemical sensitizers and irradiated with, for example, UV, visible, gamma or X-ray radiation. In particular, quaternary ammonium or phosphonium substituted, halo-psoralen compounds are described as being useful.Type: GrantFiled: July 13, 1993Date of Patent: May 23, 1995Assignee: Cryopharm CorporationInventors: Matthew S. Platz, Raymond P. Goodrich, Jr., Nagendar Yerram
-
Patent number: 5409827Abstract: The present invention provides media and methods for the maintenance or promotion of growth of a cellular line, particularly a hybridoma cellular line. A serum blend is disclosed comprising fetal bovine serum and agamma bovine calf serum. The serum blend is added to other types of support media and can be placed in association with a hybridoma cellular line. The cellular media are preferably employed with hybridoma cellular lines in an environment having a carbon dioxide atmosphere in the range from about ambient levels to 10%, and at a temperature in the range from about 32.degree. C. to 40.degree. C.In addition, the present invention provides for cellular lines maintained and grown in association with such a serum blend. Also, a serum used in a medium for producing diagnostic and therapeutic biologicals from cellular lines, particularly, hybridoma cellular lines, comprising a serum blend of fetal bovine serum and agamma bovine calf serum is provided.Type: GrantFiled: November 4, 1993Date of Patent: April 25, 1995Assignee: HyClone Laboratories, Inc.Inventor: Dale G. Kern
-
Patent number: 5407673Abstract: Disclosed is a fibrinolysis and fibrinogenolysis treatment which includes parenterally introducing into the body of a human patient human plasmin in fibrinolytically and fibrinogenolytically active form at a concentration and for a time sufficient to permit fibrinolytically and fibrinogenolytically active human plasmin to reach a concentration about the site of any intravascular clot sufficient to lyse the clot and/or to reduce circulating fibrinogen levels.Type: GrantFiled: October 6, 1993Date of Patent: April 18, 1995Assignee: Orion Therapeutic Systems, Inc.Inventors: Edward Reich, Thomas G. Easton
-
Patent number: 5401653Abstract: A method for culturing insect cells using fish serum. The method uses serum extracted from the blood of fish to culture insect cells for various purposes. The technique has the key advantages of consistent quality, low cross reactivity, safety from infectious agents that would endanger researchers or humans and animals receiving cell culture products as therapy and has appropriate nutrients to maintain the growth of insect cells. Fish serum is used together with designated defined medium to allow insect cells to grow and populations to be maintained. The method may also be used to prevent the attachment of insect cells to cultureware. Serum is derived from the blood of captive stocks of fishes raised under control conditions.Type: GrantFiled: February 23, 1994Date of Patent: March 28, 1995Assignee: Sea Run Holdings, Inc.Inventors: Evelyn S. Sawyer, Philip J. Sawyer
-
Patent number: 5397578Abstract: A method for treating chronic, purulent, middle otitis in children, comprising administering, through a perforation into a middle ear cavity, a freshly prepared donor plasma of one of the parents having the identical blood group to fill up the cavity (1,5-2,0 ml 3-4 times within 24 hours with the preliminary washing of the cavity with a physiological solution prior to each administration.Type: GrantFiled: March 29, 1994Date of Patent: March 14, 1995Assignee: Tovarischestvo s ogranichennoi otvetstvennostiju "Taurus"Inventors: Vyacheslav N. Lazarev, Alexandr S Skryabin, Alexei J. Ivoilov
-
Patent number: 5328844Abstract: The present invention provides a culture medium designated COF 1769 useful for establishing, growing and maintaining mammalian cells in culture, in particular for the establishment and culture of human normal and malignant cells. Also provided by the invention is an improved method for obtaining growth of mammalian cells.Type: GrantFiled: June 24, 1992Date of Patent: July 12, 1994Assignee: University of Colorado Foundation, Inc.Inventor: George E. Moore
-
Patent number: 5321129Abstract: Novel compounds having the general formulaS--Ar--Xin whichS denotes a saccharide residueAr denotes an aryl residue andX denotes a straight-chained or branched alkyl residue with 2 to 20 carbon atoms,provided that the aryl residue may not be a 4-ethylphenyl, 4-isopropylphenyl, 4-sec.-butyl or 4-dodecylphenyl residue if the saccharide is a galactopyranoside residue, are interesting surface-active agents and are particularly suitable in diagnostic tests in order to clear serum.Type: GrantFiled: May 14, 1992Date of Patent: June 14, 1994Assignee: Boehringer Mannheim GmbHInventors: Peter Sluka, Hans-Georg Batz, Bernd Vogt
-
Patent number: 5318782Abstract: A method for isolating tissue repair promoting substances from human or animal blood, which method comprises collecting the human or animal blood from a single human or animal individual in a first container of a container system comprising at least first and second interconnected containers; centrifuging the container system containing said blood so as to separate the blood in various fractions including a plasma fraction; transferring at least part of the plasma fraction to said second container of the container system; subjecting the plasma fraction in said second container to a low temperature so as to obtain a precipitate comprising tissue repair promoting substances; concentrating said precipitate in said second container so as to obtain a first fraction comprising a major part of the non-precipitated material, and a second fraction comprising at least the major part of the precipitate and a minor part of the non-precipitated material; and separating said second fraction comprising the tissue repair proType: GrantFiled: February 25, 1993Date of Patent: June 7, 1994Inventor: Ulla S. Weis-Fogh
-
Patent number: 5240714Abstract: A highly purified, Na.sup.+,K.sup.+ -ATPase inhibitory factor is disclosed herein. The factor does not cross-react with anti-digoxin antibody and exhibits uniquely characteristic UV absorbance maxima at approximately 202-210 nm and at 274-280 nm. The inhibitory factor has a molecular weight of less than 1000 Daltons, is non-peptidic, non-lipidic, and loses activity following charring or alkaline hydrolysis. The factor is useful as a pharmaceutical composition in methods for treating essential hypertension, cardiac malfunction and in regulating angiogenesis and active sodium transport and other conditions. Methods for purifying the factor from tissue and fluid extracts are also disclosed.Type: GrantFiled: August 29, 1989Date of Patent: August 31, 1993Inventor: Jose M. S. Rof